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ABSTRACT
Objectives To explore the prognostic value of subclinical 
cardiovascular (CV) imaging measures and serum cardiac 
biomarkers in systemic sclerosis (SSc) for the development 
of CV outcomes of primary heart involvement (pHI).
Methods Patients with SSc with no clinical SSc- pHI and 
no history of heart disease underwent cardiovascular 
magnetic resonance (CMR) imaging, and measurement 
of serum high- sensitivity- troponin I (hs- TnI) and N- 
terminal- pro- brain natriuretic peptide (NT- proBNP). 
Follow- up clinical and CV outcome data were recorded. CV 
outcomes were defined as myocarditis, arrhythmia and/or 
echocardiographic functional impairment including systolic 
dysfunction and/or diastolic dysfunction.
Results Seventy- four patients with a median (IQR) age 
of 57 (49, 63) years, 32% diffuse cutaneous SSc, 39% 
interstitial lung disease, 30% Scl70 + were followed up for 
median (IQR) 22 (15, 54) months. Ten patients developed 
CV outcomes, comprising one patient with myocarditis 
and systolic dysfunction and nine arrhythmias: three non- 
sustained ventricular tachycardia and six supraventricular 
arrhythmias. The probability of CV outcomes was 
considerably higher in those with NT- proBNP >125 pg/
mL versus normal NT- proBNP (X2=4.47, p=0.035). Trend 
for poorer time- to- event was noted in those with higher 
extracellular volume (ECV; indicating diffuse fibrosis) and 
hs- TnI levels versus those with normal values (X2=2.659, 
p=0.103; X2=2.530, p=0.112, respectively). In a predictive 
model, NT- proBNP >125 pg/mL associated with CV 
outcomes (OR=5.335, p=0.040), with a trend observed for 
ECV >29% (OR=4.347, p=0.073).
Conclusion These data indicate standard serum cardiac 
biomarkers (notably NT- proBNP) and CMR indices of 
myocardial fibrosis associate with adverse CV outcomes in 
SSc. This forms the basis to develop a prognostic model in 
larger, longitudinal studies.
INTRODUCTION
Systemic sclerosis (SSc, scleroderma) is a 
rare immune- mediated inflammatory disease 
(IMID) characterised by autoimmunity, 
vasculopathy and fibrosis of the skin and 
internal organs. It can be fatal especially 
when the lung, heart and/or kidneys are 
affected.1 2 Clinically overt SSc- primary heart 
involvement (SSc- pHI) (ie, not secondary to 
ischaemic heart disease (IHD), or pulmonary 
artery hypertension, PAH) typically manifests 
as myocarditis, conduction abnormalities and 
arrhythmia and/or heart failure. SSc- pHI is 
described in up to 20%–30% of patients with 
SSc3 4 and is associated with a mortality rate of 
up to 70%.5 6 Historical autopsy studies and 
sensitive multiparametric imaging methods 
such as cardiovascular magnetic resonance 
(CMR) imaging suggest subclinical heart 
involvement in a majority of patients with 
SSc.7–10 Late gadolinium enhancement (LGE) 
CMR in SSc detects focal myocardial fibrosis 
that is distinct from scar caused by epicar-
dial coronary artery disease.7 9 CMR with 
native T1 and extracellular volume (ECV) 
Key messages
What is already known about this subject?
 ► Systemic sclerosis primary heart involvement (SSc- 
pHI) is associated with increased mortality.
 ► Subclinical SSc- pHI, including cardiovascular mag-
netic resonance (CMR) and blood indicators are 
commonly described however, the prognostic signif-
icance is unclear.
What does this study add?
 ► Cardiac biomarkers, in particular N- terminal- pro- 
brain natriuretic peptide and CMR indices sug-
gestive of diffuse myocardial fibrosis (extracellular 
volume), showed association with cardiovascular 
(CV) outcomes.
How might this impact on clinical practice or 
further developments?
 ► These data can inform a prognostic risk model of 
clinical SSc- pHI, aid early identification and prevent 
CV death in SSc.
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measurement indicates diffuse myocardial fibrosis and 
has been reported in up to 70% of patients with SSc.11–13 
Finally, myocardial perfusion impairment due to coro-
nary microvascular dysfunction has also been observed 
in patients with SSc.7 14 15 Serum cardiac biomarkers 
troponin I (TnI) and N- terminal pro- brain natriuretic 
peptide (NT- proBNP) have similarly emerged as sensitive 
tools in the detection of heart involvement.16 Elevated 
cardiac biomarkers have been observed in patients with 
SSc and associated with cardiovascular (CV) events while 
more recent data also demonstrate their association with 
subclinical SSc- pHI.15 17
The prognostic implication of subclinical SSc- pHI 
however has not been established. Only a subgroup 
of patients with subclinical SSc- pHI develop clinically 
overt SSc- pHI. Identifying patients at risk of clinically 
meaningful SSc- pHI and the indices associated with 
progression to clinical presentation is an unmet need. 
We recently reported on one of the largest studies to 
describe subclinical CMR features of SSc- pHI, demon-
strating reduced microvascular perfusion and presence 
of myocardial focal and diffuse fibrosis in 83 patients with 
SSc.18 This subclinical phenotype associated with high- 
sensitivity (hs)- TnI and NT- proBNP and also SSc disease 
severity and complicated peripheral vasculopathy. We 
now report on the clinical and functional outcomes of 
this cohort. The principal aim was to explore the prog-
nostic value of CMR and serum cardiac biomarkers for 
the development of CV outcomes of SSc- pHI.
METHODS
Study design
We report on patients recruited as part of two observa-
tional studies from 2013 to 2019 at the Department of 
Rheumatology, The Leeds Teaching Hospital NHS Trust 
(‘Connective Tissue Disease and Vasculitis Cohort’ and 
‘ELectrophysiology and CArdiac imaging in Sclero-
dermA’ (ELCASA) study). The studies were conducted 
according to the Declaration of Helsinki. All participants 
provided written informed consent.
Patients
All patients fulfilled the 2013 American College of 
Rheumatology/EULAR criteria for SSc19 and were clas-
sified as limited cutaneous SSc or diffuse cutaneous SSc 
(dcSSc), respectively, according to the LeRoy classifica-
tion.20 Exclusion criteria included any prior diagnosis of 
SSc- pHI or other cardiomyopathies, arrhythmia/rhythm 
disturbances, valve disease, abnormal systolic or diastolic 
(>grade 1) function, a diagnosis of PAH, IHD, diabetes 
or more than two traditional CV risk factors defined as 
current smoker, hypertension, hypercholesterolaemia/
hypertriglyceridaemia and family history of premature 
CV disease (CVD). Patients with any other inflammatory 
musculoskeletal conditions were also excluded. All partic-
ipants were followed up for a minimum of 12 months.
Schedule of assessments
Clinical data
Comprehensive demographic and clinical data were 
collected including SSc subtype, duration, serology, 
organ involvement, any prior diagnosis of heart disease, 
current and previous immunosuppression and nailfold 
capillaroscopy findings.
Testing and assessments
All patients had annual Doppler echocardiography as per 
standard practice with additional testing, including ECG, 
24- hour Holter ECG and stress ECG if clinically indi-
cated. The ‘ELCASA’ cohort15 also had an implantable 
loop recorder (ILR) (Medtronic Reveal XT) inserted 
and 24- hour Holter monitor yearly. These patients were 
followed for 3 years and had the ILR interrogated every 
3 months up until April 2017, after which they continued 
with testing for the wider group as described above.
Serum cardiac biomarker testing
The whole cohort had baseline serum samples collected 
for hs- TnI and NT- proBNP testing, measured using the 
same technique. Hs- TnI was measured on a Siemens Advia 
XPT system (Advia Chemistry XPT and Advia Centaur 
XPT Immunoassay, respectively) and NT- proBNP on 
Cobas 6000 (immunochemistry module Cobas e601) 
and the kits supplied by Roche Diagnostics. According 
to the manufacturer recommendations, a concentration 
above 37 ng/mL for hs- TnI and above 125 ng/mL for 
NT- proBNP constituted abnormal.
CMR imaging
CMR was performed at baseline, on a 3 Tesla Philips 
Achieva MR system, as previously described.15 18 21 The 
same CMR protocol was used for the whole cohort and 
comprised left ventricle (LV) function and volume, LGE, 
native and post- contrast T1 mapping for ECV estimation 
and adenosine stress and rest myocardial perfusion with 
myocardial blood flow (MBF) and myocardial perfusion 
reserve (MPR) assessment. Cvi42 software (V.4.1.3, Circle 
Cardiovascular Imaging, Calgary, Canada) was used for 
CMR image analysis. LGE was reported according to the 
16 segment American Heart Association (AHA) model22 
and the five- SD method was used for LGE mass quantifi-
cation.23 Native and post- contrast myocardial and blood 
pool T1 were measured in order to calculate ECV.24 
Perfusion was assessed visually by comparing the rest 
and stress perfusion images using the 16 segment AHA 
model.22 Quantitative analysis of the perfusion data were 
also performed to generate estimates of MBF at stress 
and rest.25 MPR values were calculated by dividing the 
stress by the rest MBF. According to the departmental 
reference ranges, an ECV >29% and T1 native >1240 ms 
were classified as abnormal.
Study endpoint
Any CV outcomes that occurred up to the end of study 
period were recorded. The primary endpoint of clin-
ically relevant SSc- pHI was defined as any episode of 
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myocarditis, rhythm disturbances including supraven-
tricular, ventricular and atrioventricular block and/
or clinically relevant (echocardiographic) functional 
impairment including systolic dysfunction (defined as 
a left ventricular ejection fraction <50%) and/or a dias-
tolic dysfunction >grade 1 (defined as an E/A ratio >0.8; 
deceleration time <200 ms).
Statistical analysis
Student t- test and Mann- Whitney U for continuous varia-
bles and Fisher’s exact test for categorical variables were 
used to assess for significant between group differences. 
Kaplan- Meier survival curves and log- rank test were 
performed to plot cumulative time- to- event outcomes 
between groups. Univariate logistic regression was used 
to identify association between CV outcomes and CMR 
and cardiac serum biomarkers. The penalised maximum 
likelihood estimation method was employed to eval-
uate the predictive value of CMR measures and cardiac 
biomarkers for the development of CV outcomes. Prin-
cipal components analysis was applied over all CMR vari-
ables to predict missing values in the model. With this 
pilot study, a two- tailed p value of 0.05 was used to indi-
cate strength of finding as opposed to assigning statistical 
significance. The statistical analysis was performed using 
SPSS (IBM SPSS Statistics 22) and R (V.3.5.2).
RESULTS
Baseline characteristics
Seventy- four patients with SSc had available baseline and 
follow- up outcome data and were included in the study. 
Eighteen of these had an ILR implanted. Participants had 
a median (IQR) age of 57 (49, 63) years, 24 (32%) had 
dcSSc and 29 (39%) had a history of interstitial lung disease 
(ILD). Twenty- seven (36%) were anti- centromere antibody 
(ACA) positive and 22 (30%) were anti- topoisomerase anti-
body (Scl70) positive (table 1). Forty- two (57%) patients 
were receiving a disease modifying anti- rheumatic drug at 
the time of recruitment. Twenty- one (28%) patients had 
CV risk factors, 16 had one CV risk factor and 5 had two CV 
risk factors. None of the patients had any rhythm distur-
bances, evidence of IHD on ECG or evidence of functional 
impairment on CMR.
Cardiovascular outcomes
Patients were followed up for a median (IQR) of 22 (15, 
54) months. Eleven CV outcomes in 10 patients were 
recorded, comprising one diagnosis of myocarditis (new 
clinical presentation; associated with LV systolic dysfunc-
tion, with subsequent CMR confirmation) and patients 
with arrhythmias (table 2). The arrhythmias included 
three non- sustained ventricular tachycardia (NSVT) and 
six supraventricular arrhythmias; of which one patient had 
atrial tachycardia, three atrial fibrillation of which one 
also had atrial flutter, one patient with atrial flutter and 
another one with supraventricular tachycardia. For seven 
out of nine patients with SSc the arrhythmias were picked 
up by the ILR, only one patient being symptomatic (with 
palpitations) at the time of the arrhythmia. Two addi-
tional patients with SSc developed atrial tachycardia and 
NSVT detected on 24- hour Holter ECG and stress ECG, 
investigations that were carried out following an episode 
of syncope and dizziness with palpitations, respectively.
None of the 74 patients had diastolic dysfunc-
tion >grade 1. The median (IQR) time to CV outcome 
was 14 (8, 27) months. The patients with SSc with CV 
outcomes had a median (IQR) baseline age and disease 




Age, median (IQR) 57 (49, 63)
Female 63 (85)
Disease subtype
  lcSSc 50 (68)
  dcSSc 24 (32)
Disease duration (years), median (IQR) 8 (2, 16)
History of
  Digital ulceration 16 (22)
  Calcinosis 17 (23)
  Myositis 3 (4)
  GORD 66 (90)
  Interstitial lung disease 29 (39)
Current use of DMARD 42 (57)
Clinical profile
  Total modified Rodnan skin score, median 
(IQR)
2 (1, 6)
  Digital ulceration 10 (14)
  Tendon friction rubs 2 (3)
  Calcinosis 14 (19)
Antibody profile
  ANA 69 (93)
  ACA 27 (36)
  Scl70 22 (30)
CV risk factors
  Any CV risk factors, 21 (28)
   FHx premature CVD 8 (11)
   Smoking 6 (8)
   Dyslipidaemia 3 (4)
   HBP 8 (11)
One CV risk factor 16 (21)
Two CV risk factors 5 (7)
N % presented unless stated otherwise.
ACA, anti- centromere antibody; ANA, antinuclear antibodies; 
CV, cardiovascular; CVD, cardiovascular disease; dcSSc, diffuse 
cutaneous systemic sclerosis; DMARD, disease modifying 
anti- rheumatic drugs; ESR, erythrocyte sedimentation rate; 
FHx, family history; GORD, gastro- oesophageal reflux disease; 
HBP, high blood pressure; lcSSc, limited cutaneous systemic 
sclerosis; Scl70, anti- topoisomerase antibody; SSc, systemic 
sclerosis.
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duration of 58 (52, 64) and 2 (1, 22) years, respectively, 
nine were female, five had dcSSc, four had a diagnosis 
of ILD, three were Scl70 and five were ACA positive. All 
patients were in sinus rhythm, and none had presenta-
tions of IHD.
CV outcomes and CMR indices
Of the 72 patients with available LGE data, 14 had focal 
LGE fibrosis in a non- coronary distribution. Only one of 
these sustained a CV outcome. The other eight patients 
with CV outcomes showed no LGE (available LGE data 
in 9 out of 10 that sustained a CV outcomes) (table 3). 
Seventy- one of 74 patients had available ECV data of 
which 9 had a CV outcome. An ECV >29% was recorded 
in 8/9 patients with SSc with CV outcomes versus 40/62 
patients with no CV outcomes (table 3). In other words, 
48/71 patients with SSc had an ECV above the normal 
threshold (>29%) of which 8 sustained a CV outcome 
compared with only 1/23 patients with SSc with normal 
ECV (of available ECV data in 9/10 that sustained a CV 
outcome). Numerically higher LV mass was noted in 
those with CV outcomes (mean (SD) 48 (10) vs 43 (10), 
p=0.102) (table 3) although within normal range.26 
There was no difference in MPR between those with 
and without CV outcomes (median (IQR) 1.86 (1.5, 2.4) 
vs 1.96 (1.6, 2.5), respectively, p=0.696). The mean LV 
volume and function were within normal range, with no 
suggestion of impairment in those with a CV outcome.
CV outcomes and serum cardiac biomarkers
Patients with CV outcomes had modestly higher hs- TnI 
(median (IQR) 5 (3, 127) vs 3 (3, 7), respectively, p=0.116) 
and higher NT- proBNP (median (IQR) 134 (88, 298) vs 
83 (48, 124), respectively, p=0.114) compared with those 
with no CV outcomes. A NT- proBNP above the normal 
reference range (>125 pg/mL) was recorded in 6/10 
patients with CV outcomes versus 15/64 patients with no 
CV outcomes (p=0.026) (table 3). That is, CV outcomes 
were recorded in 6/10 with NT- proBNP above the normal 
range (>125 pg/mL) and in 4/53 patients with normal 
NT- proBNP levels. An abnormal hs- TnI was noted in 2/9 
patients with CV outcomes versus 4/61 patients with no 
CV outcomes (table 3). Therefore, of the 70 patients 
with available hs- TnI data, CV outcomes occurred in 2/6 
patients with abnormal hs- TnI (>37 ng/L) and in 7/64 
with normal hs- TnI levels.
Probability of CV outcomes in those with and without 
abnormal CMR and cardiac serum biomarkers
The probability of CV outcomes was higher in those with 
NT- proBNP above the normal threshold compared with 
those with normal NT- proBNP levels (X2=4.47, p=0.035) 
(figure 1). A trend in those with higher ECV compared 
with those with normal ECV values (X2=2.659, p=0.103) 
(figure 1) and in those with hs- TnI above the normal 
threshold (≥37) compared with those with normal hs- TnI 
levels was also observed (X2=2.530, p=0.112). The prob-
ability of CV outcomes did not differ between patients 
with LGE compared with those with no LGE (X2 = 0.250, 
p=0.617) (figure 1).
CMR and cardiac biomarkers as predictors of CV outcomes
Univariate logistic analysis showed an association of 
NT- proBNP above the normal threshold (>125 pg/mL) 
with the presence of CV outcomes (OR=4.90, p=0.025). 
Hs- TnI also associated with the presence of CV outcomes 
(OR=1.009, p=0.040). There was no association between 
Table 2 Baseline characteristics of patients with CV outcomes
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10




NSVT NSVT NSVT Myocarditis
systolic 
dysfunction





Age (years) 74 62 57 73 49 55 52 59 50 60
Gender F F F F F F F F M F
SSc subset lcSSc lcSSc dcSSc lcSSc lcSSc lcSSc dcSSc dcSSc dcSSc dcSSc
ILD No No No No No No Yes Yes Yes Yes
MRSS 6 4 14 2 2 6 11 18 0 9
ANA ACA ACA – ACA ACA ACA Scl70 Anti Ro Scl70 Scl70
History of DU Yes No No No No Yes No No No No
NT- proBNP 
(pg/mL)
161 288 105 127 32 141 329 105 38 470
Hs- TnI (ng/L) 3 5 3 – 6 31 313 5 3 225
ACA, anti- centromere antibody; AF, atrial fibrillation; ANA, antinuclear antibodies; CV, cardiovascular; dcSSc, diffuse cutaneous systemic sclerosis; 
DU, digital ulcers; hs- TnI, high- sensitivity troponin I; IcSSc, limited cutaneous systemic sclerosis; ILD, interstitial lung disease; MRSS, modified 
Rodnan skin score; NSVT, non- sustained ventricular tachycardia; NT- proBNP, N- terminal pro- brain natriuretic peptide; Scl70, anti- topoisomerase 
antibody; SR, sinus rhythm; SSc, systemic sclerosis; SVT, supraventricular tachycardia; VE, ventricular ectopics.
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LGE or LGE% and CV outcomes (OR=0.481, p=0.508; 
OR=1.003, p=0.990, respectively) at univariate analysis. 
A predictive model was built using penalised likelihood 
estimation that included CMR variables and cardiac 
biomarkers. NT- proBNP above the normal threshold 
was the only variable associated with the development 
of CV outcomes (OR=5.335, p=0.040) although an ECV 
above 29% almost reached similar strength (OR=4.347, 
p=0.073) (table 4).
DISCUSSION
This study evaluates the association of subclinical (CMR 
and blood) indicators of SSc- pHI (not wider CVD) for 
future development of CV events. Just under 15% (10/74) 
of this cohort developed CV outcomes including myocar-
ditis, systolic dysfunction and arrhythmias. NT- proBNP 
indicating subclinical contractile impairment associated 
with future CV outcomes, with a similar trend of an 
imaging marker indicative of diffuse fibrosis (measured 
as higher ECV on CMR).
A significant proportion of unselected patients with 
SSc have subclinical cardiac involvement when sensi-
tive methods are used.27–30 We and others have demon-
strated the presence of focal and diffuse fibrosis as 
well as microvascular impairment on CMR.14 18 31 
The prognostic implications of such subclinical CMR 
abnormalities are however not established. Several 
cross- sectional studies demonstrate an association 
between LGE burden and ventricular arrhythmia as 
assessed by 24hour Holter ECG,32–34 while other studies 
do not confirm these findings.7 35 Preliminary results 
from our group demonstrated association of CMR- 
ECV with arrhythmias on implantable loop recording 
as well as higher hs- TnI and NT- proBNP levels in 
patients with SSc with confirmed electrophysiological 
abnormalities.15
Table 3 CMR parameters and cardiac biomarkers in patients with SSc with CV outcomes versus patients with SSc with no 
CV outcomes
Patients with SSc with CV 
outcomes
Patients with SSc with no 
CV outcomes P value
CMR variable
  Myocardial inflammation and fibrosis
   ECV% 31 (2) 30 (3) 0.61
   ECV >29, n% 08 September 40/62 Fisher’s exact test 0.254
   T1 native (ms) 1216 (88) 1237 (72) 0.434
   T1 native >1240 ms, n% 5/9 33/64 Fisher’s exact test 1
   LGE presence 1/9 13/63 Fisher’s exact test 0.679
   Fibrosis mass 0.42 (1.27) 0.45 (1.2) 0.931
   LGE% (from LV mass) 0.60 (1.8) 0.59 (1.5) 0.822
  Myocardial perfusion
   MPR, median (IQR) 1.86 (1.5, 2.4) 1.96 (1.6, 2.5) 0.696
   Stress MBF, median (IQR) 1.98 (1.8, 2.6) 1.93 (1.4, 2.7) 0.635
   Rest MBF, median (IQR) 1.21 (0.8, 1.4) 0.99 (0.7, 1.2) 0.339
  LV dimension and function
   LVEDV/BSA (ml/m2) 76 (15) 80 (14) 0.408
   LVESV/BSA (ml/m2) 30 (8) 30 (9) 0.926
   LVSV/BSA (ml/m2) 50 (7) 47 (7) 0.191
   LV mass/BSA (g/m2) 48 (10) 43 (10) 0.102
   LVEF % 63 (5) 62 (5) 0.496
Cardiac biomarkers
   hs- TnI, median (IQR) 5 (3,128) 3 (3, 7) 0.116
   hs- TnI >37 ng/L, n% 2/9 4/61 Fisher’s exact test 0.168
   NT- proBNP, median (IQR) 134 (88, 298) 83 (48, 124) 0.114
   NT- proBNP >125 pg/mL, n% 6/10 15/64 Fisher’s exact test 0.026*
Mean (SD) unless stated otherwise.
*p<0.05.
BSA, body surface area; CMR, cardiovascular magnetic resonance; CV, cardiovascular; ECV, extracellular- volume fraction; EDV, end- 
diastolic volume; EF, ejection fraction; ESV, end- systolic volume; hs- TnI, high- sensitivity troponin I; LGE, late gadolinium enhancement; 
LV, left ventricular; MBF, myocardial blood flow; MPR, myocardial perfusion reserve; NT- proBNP, N- terminal pro- brain natriuretic 
peptide; SSc, systemic sclerosis; SV, stroke volume.
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The current study sought to build on this further 
to explore the value of CMR and cardiac biomarkers 
in the development of a future prognostic model for 
predicting SSc- pHI CV outcomes. Several studies have 
investigated the prognostic value of CMR for predicting 
CV outcomes in a longitudinal cohort.34 36 The Sclero-
derma Arrhythmia Clinical Utility Study included 150 
patients with SSc and reported predictive value of 
increased T2 ratio, a marker of myocardial oedema 
and LGE% for the development of ventricular rhythm 
disturbances and sudden cardiac death in SSc. Another 
study in 40 consecutive patients with SSc that had T1 
mapping and diffusion- weighted imaging CMR showed 
association of T1 native with the occurrence of CV 
events37 while Bordonaro et al, looking retrospectively 
at a symptomatic SSc cohort reported LGE, T1 native 
and ECV as independent predictors of CV events.38 
These studies included patients with both primary and 
secondary CVD, capturing real- life cohorts. Our study is 
focusing on primary SSc cardiac pathology; in order to 
understand pathophysiology of SSc- pHI and to inform 
on risk stratification. We thus excluded patients with 
any prior diagnosis of heart disease, that comprised 
cardiomyopathies, heart failure, valve disease, PAH, 
IHD, diabetes and more than two CV risk factors at 
baseline and defined CV outcomes that were attribut-
able to SSc- pHI. Fourteen per cent of the patients devel-
oped CV outcomes consistent with SSc- pHI including 
myocarditis, supraventricular and ventricular arrhyth-
mias. NT- proBNP associated with the development of 
CV outcomes, indicating that measures of subclinical 
myocardial contractile impairment in a cohort with 
otherwise no clinical suggestion of cardiac involve-
ment, precedes the development of CV outcomes in 
SSc. Given the ease and low cost of blood biomarkers, 
this finding will provide an accessible means of strati-
fying for SSc- pHI. Hs- TnI did not clearly associate with 
CV outcomes. This is perhaps expected as hs- TnI is an 
indicator of myocardial injury, associated with acute 
CV events. The time of serum hs- TnI sampling in this 
asymptomatic cohort is thus particularly relevant as 
may be the relatively small sample size, limiting ability 
of prediction. A longitudinal study with more frequent 
sampling for hs- TnI (and NT- proBNP) would clarify 
this further. Several other studies have also suggested 
an association of higher NT- proBNP and hs- Tn levels 
with the development of CV events in patients with 
SSc.15 39 No studies however explored the value of 
Figure 1 Time- to- event plots for cardiovascular outcomes. (A) Time- to- event plots in patients with normal and abnormal NT- 
proBNP. (B) Time- to- event plots in patients with normal and abnormal hs- TnI. (C) Time- to- event plots in patients with normal 
and abnormal ECV. (D) Time- to- event plots in patients with and without LGE. ECV, extracellular volume; hs- TnI, high- sensitivity 
troponin I; LGE, late gadolinium enhancement; NT- proBNP, N- terminal pro- brain natriuretic peptide.
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cardiac biomarkers in association with CMR indices for 
the development of SSc- pHI in a longitudinal cohort.
ECV, suggestive of diffuse myocardial fibrosis showed 
a trend for association with CV outcomes. Eight of 
nine subjects with a CV outcome had an ECV above 
the normal threshold (>29%)—although raised ECV 
was common also in patients without CV events. Time- 
to- event plots showed that patients with higher ECV 
had more CV outcomes. Increasing data from isch-
aemic and non- ischaemic cardiomyopathies demon-
strate the prognostic relevance of T1 mapping indices 
(native T1 and ECV) in predicting CV events and we 
have recently documented the presence of higher ECV 
in patients with SSc and significant arrhythmias.15 40 41 
Fibrosis, in particular diffuse fibrosis might thus repre-
sent the substrate for the development of CV outcomes 
and a sensitive marker in the early detection of future 
SSc- pHI.
Only 1 of the 14 patients with focal fibrosis on LGE 
had a CV outcome (ie, of 10 subjects with a CV outcome, 
only 1 subject showed focal fibrosis LGE). The relatively 
small sample size and event ratio as well as the relatively 
low extent of fibrosis in our study likely accounts for 
the lack of an association between CV outcome and 
LGE, which is inconsistent with other studies. However, 
the extent and location of LGE need to be taken into 
consideration as these are important determinants for 
the development of arrhythmias and CV events in both 
ischaemic and non- ischaemic cardiomyopathies.42 43 
These data imply scar mass may be more modest in SSc- 
pHI and thus of limited utility.
Both lower and higher LV mass have been reported 
in different IMID44–46; in our study, patients with 
confirmed SSc- pHI CV outcomes had greater LV mass, 
although this did not reach significance. Increased LV 
mass and LV hypertrophy are recognised as predictors 
of sudden cardiac death and arrhythmia in different 
cardiac pathologies.47 48 Further research is needed to 
clarify the significance of increased LV mass in SSc.
This study also investigated the association between 
myocardial perfusion and the development of CV 
outcomes, with no association demonstrated. The 
significance of myocardial microvascular impairment in 
SSc needs to be further addressed in longer follow- up 
studies.
This study has some limitations. While this is a good- 
sized longitudinal follow- up study in the context of the 
existing literature, larger cohorts and longer follow- up 
with more events will be needed to conclusively deter-
mine the prognostic value of abnormal CMR indices. 
An inception cohort and/or more patients with early 
disease would be more representative to avoid selec-
tion bias and potentially miss CV outcomes occurring 
early in the disease. T2- weighted imaging, a common 
sequence used for the detection of myocardial inflam-
mation was not included in the CMR protocol, however, 
T1 mapping, proven to have superior diagnostic accu-
racy in detecting myocardial oedema and fibrosis was 
instead used.49 50 We combined two cohorts that had 
different monitoring methods. The majority of patients 
with arrhythmia were from the smaller cohort with ILR 
monitoring and were asymptomatic. CV outcomes may 
have been missed in the non- ILR group, potentially 
underestimating the event rates of the study. Most of 
the observed endpoints were arrhythmias occurring 
in the atria. Despite the known link between myocar-
dial disease and atrial arrhythmia, this observation 
may partly explain the lack of correlation between 
focal fibrosis as measured with LGE and the clinical 
endpoints in this study. Blood biomarkers and ECV 
appear more predictive of atrial arrhythmias as they are 
more general markers of cardiac disease.
In conclusion, this study provides initial evidence for 
a prognostic risk model of clinical SSc- pHI and iden-
tifies in particular NT- proBNP and potentially diffuse 
myocardial fibrosis by CMR as associating with future 
CV events. Larger, longitudinal studies are required to 
confirm the findings and inform risk stratification for 
future development of CV outcomes of SSc- pHI.
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